Cencora, Inc. (NYSE:COR – Free Report) – Stock analysts at Leerink Partnrs raised their FY2028 EPS estimates for shares of Cencora in a note issued to investors on Wednesday, April 2nd.

Have you been paying attention to shares of Cencora (COR)? Shares have been on the move with the stock up 8.3% over the past month. The stock hit a new 52-week high of $271.86 in the previous session.

Alto and Cencora are collaborating to deliver enhanced patient support services and streamline access to prescribed specialty medications. The collaboration leverages Cencora’s patient support ...

Shares of Cencora stock opened at $251.40 on Tuesday. The stock has a market cap of $48.75 billion, a price-to-earnings ratio of 35.76, a price-to-earnings-growth ratio of 1.31 and a beta of 0.49 ...

Have you been paying attention to shares of Cencora (COR)? Shares have been on the move with the stock up 6.2% over the past month. The stock hit a new 52-week high of $262.56 in the previous session.

Wells Fargo raised the firm’s price target on Cencora (COR) to $274 from $251 and keeps an Equal Weight rating on the shares. The firm is updating its model following Cencora’s results and ...